(Q40459921)

20 September 2017

Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies. (English)

1 reference

20 September 2017

1 reference

Edward Htun van der Horst

1

1 reference

20 September 2017

Marta Murgia

2

1 reference

20 September 2017

Martin Treder

3

1 reference

20 September 2017

Axel Ullrich

4

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

International Journal of Cancer

20 September 2017

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

20 September 2017

115

1 reference

20 September 2017

4

1 reference

20 September 2017

519-527

1 reference

20 September 2017

Anticancer antibodies

1 reference

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

21 January 2018

1 reference

Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials

21 January 2018

1 reference

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.20867

1 reference

20 September 2017

1 reference